Triassic completes 330 million RMB Series B financing, and Jingwei China and CPE Yuanfeng jointly lead the investment

Recently, Nanjing Sandieji Pharmaceutical Technology Co., Ltd. (“Sandieji” for short) completed a series B financing of 330 million yuan. This round of financing was jointly led by Matrix Partners China and CPE Yuanfeng, followed by the Shanghai Science and Technology Innovation Fund. The original shareholders, Morningside Venture Capital, Daotong Investment, and Yunqi Capital continued to support the investment. China Renaissance Capital acted as the exclusive financial advisor for this round of financing. This round of funding will accelerate the company’s 3D Printing drug product development and commercial expansion, and advance Triassic’s vision of opening a new era of global smart pharmaceuticals.

According to public information, Sandieji was established in 2015 and is the only 3D Printing drug company in China. It is committed to building a new 3D printing drug technology platform, forming a full chain of expertise from drug formulation design, digital development, to intelligent production. There is technology. At present, as the first Chinese pharmaceutical company to be selected for the US FDA’s emerging technology project, Sandieji is participating in the formulation of the US Pharmacopoeia 3D printing drug industry standards. The core technology of Triassic is the world’s first Melt Extrusion Deposition (MED) 3D printing technology.

This 3D printing technology tailored for pharmaceutical production has strong universality and completely overturns the tradition. Drug product development and pharmaceutical methods. Based on this world-leading 3D printing drug technology, Triassic pioneered the “Formulation by Design (3DFbD)” digital formulation development method, transforming the traditional long-period trial-and-error formulation development model into designable , Adjustable digital development method, which greatly improves the efficiency and success rate of new drug research and development. It is worth mentioning that Triassic’s production line has achieved full-process digital production and real-time quality monitoring. Every 3D printed tablet produced is traceable, which provides a better way for drug production management and regulatory supervision. Advanced means.

Triassic has established a rich 3D printing drug delivery technology platform, through the programmed and precise control of drug release, precise control of the pharmacokinetic curve, and the development of more clinically valuable 505(b)(2) products. The first product, T19, was approved by the US FDA in January 2021 for the treatment of rheumatoid arthritis. T19 is expected to become the second approved 3D printing drug product in the world. This product has been declared to China’s NMPA through the two-class improved new drug route in June this year. The company’s second product, T20, received a positive response from the US FDA PIND in March this year and will submit the IND at the end of this year. In the next year, the company has 3 product plans to submit applications for the FDA’s PIND meeting.

In addition to developing self-developed products, Sandieji is also actively exploring various application scenarios of new technologies. The company cooperates with a number of multinational pharmaceutical companies to use MED 3D printing technology to solve the problem of poor medicinal properties of new compound drugs due to poor solubility, and to develop a new generation of drug products that can extend the life cycle of new compound drugs. In China, the company cooperates with Shanghai Huiyong and Shufang Pharmaceutical of Shanghai Pharmaceutical Group to provide partners with differentiated new drug products with market competitiveness.